Danny Sullivan

Glasgow

Contributing Editor at Longevity Technology

Contributing Editor at @LongevityTech. Writer, marketer, PR'er, traveller, reader, runner, technolover and lots of other ers...

Featured in: Favicon

longevity.technology Favicon

flipboard.com

Articles

HAYA Therapeutics harnesses the ‘dark genome’ against age-related diseases

4 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Precision medicine biotech HAYA Therapeutics has secured $65 million in Series A funding to accelerate the development of RNA-guided medicines that target chronic and age-related diseases by modulating the regulatory genome. The investment will enable the company to advance its lead therapeutic candidate into clinical trials for heart failure and to broaden its pipeline of therapies that target long non-coding RNAs (lncRNAs) in various disease contexts.
Alchemab and Lilly ink $415m neurodegeneration drug licensing deal

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp British biotech Alchemab Therapeutics this week announced a licensing agreement with pharma giant Eli Lilly for its lead investigational drug aimed at neurodegenerative conditions. The “IND-ready” drug, called ATLX-1282, is the first to emerge from Alchemab’s proprietary platform, which harnesses antibody responses from individuals who exhibit resilience to serious diseases.
Hundred Health acquires BellSant to enhance AI-powered longevity platform

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp The AI-enabled personalized healthcare market is hotting up, with the likes of Function Health and Superpower both hitting the headlines recently. This week, another player emerged as AI-driven consumer health platform Hundred Health announced the acquisition of personalized health and wellness providerBellSant in an all-stock deal aimed at integrating a wealth of longevity research into its offering.
Hidden biological ‘language’ may hold the key to unlocking lifespan extension

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Scientists at the Sagol Center for Healthy Human Longevity at Bar-Ilan University have made progress in the quest to learn why some mammals have evolved to live much longer, and comparatively healthier, lives than others.
NewLimit lands $130m to advance epigenetic reprogramming platform

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity biotech NewLimit has raised $130 million in Series B funding to advance its mission to extend human healthspan through epigenetic reprogramming. Founded with the goal of developing medicines that increase the number of healthy years in human life, NewLimit initially anticipated a long multi-year trajectory toward tangible scientific progress.
Function Health acquires full-body scanning firm Ezra

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Consumer health platform Function Health has acquired full body scanning company Ezra as it continues its push to democratize advanced preventative healthcare. Aiming to make proactive health monitoring more accessible, affordable and scalable, the acquisition unites Function’s extensive lab testing capabilities with Ezra’s AI-driven imaging to offer a longitudinal view of personal health.
UNITY Bio lays off staff and seeks ‘strategic alternatives’

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity focused biotech company UNITY Biotechnology has released complete 36-week data from its Phase 2b ASPIRE clinical study, along with a corporate update reflecting a significant shift in its direction.
Stately Bio launches to enhance cell therapy with ML-powered imaging

2 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp After three years in stealth mode, Palo Alto-based biotech Stately Bio has emerged with $12 million in seed funding for its mission to improve regenerative medicine by integrating machine learning with cell biology. The company claims its ML-powered live-cell imaging platform is capable of delivering real-time insights into the identity, quality and behavior of living cells – without harming them.
‘We’ve shown that targeting senescent cells can lead to improved outcomes’

2 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Back in March, senotherapeutic drug developer UNITY Biotechnology reported topline results from the Phase 2b ASPIRE trial evaluating its lead compound UBX1325 in patients with diabetic macular edema (DME). While the trial met many of its objectives, its failure to meet the primary endpoint saw the company’s stock fall some 30% on the news.
Therini Bio advances neurodegeneration drug to next phase

2 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Neurodegeneration-focused biotech Therini Bio has announced encouraging results from a Phase 1a clinical trial evaluating its lead drug candidate, THN391, in healthy volunteers. The therapy is being investigated for its potential as a treatment for neurodegenerative diseases by addressing fibrin-driven neuroinflammation, a key pathological process linked to vascular dysfunction.